<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787445</url>
  </required_header>
  <id_info>
    <org_study_id>20-009542</org_study_id>
    <nct_id>NCT04787445</nct_id>
  </id_info>
  <brief_title>Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension</brief_title>
  <official_title>Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension: An Exercise Hemodynamic Study (TAPH Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the clinical and hemodynamic response of&#xD;
      Pulmonary Arterial Hypertension (PAH) therapy in patients with atypical PAH and risk factors&#xD;
      for left heart disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational prospective study to better understand the clinical impact of&#xD;
      Pulmonary Arterial Hypertension (PAH) specific therapy in patients with atypical PAH among&#xD;
      those with risk factors for left heart disease&#xD;
&#xD;
      The study involves detailed baseline clinical evaluation prior to initiation of PAH therapy,&#xD;
      followed by repeat clinical assessment after 6 months of medical therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">March 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 9, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe prevalence of occult left heart disease during exercise in atypical pulmonary hypertension, as defined by pulmonary arterial wedge pressure during exercise cardiac catheterization.</measure>
    <time_frame>Baseline Catheterization</time_frame>
    <description>Pulmonary arterial wedge pressure &gt;25 mmHg during exercise cardiac catheterization will indicate occult left heart disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the therapeutic response of chronic pulmonary vasodilator therapy</measure>
    <time_frame>6 Month Catheterization</time_frame>
    <description>Favorable pulmonary vasodilatory effect will be associated a change of &gt; 10% reduction in pulmonary artery-pressure flow slope from baseline to 6 month catheterization</description>
  </primary_outcome>
  <other_outcome>
    <measure>Identify predictors on baseline exercise catheterization of subsequent exercise capacity improvement following chronic pulmonary vasodilatory therapy.</measure>
    <time_frame>6 Month Catheterization</time_frame>
    <description>From paired exercise capacity measurements of peak VO2 from baseline to 6 month testing, patients with clinically meaningful change defined by improvement following treatment of &gt;1 ml/kg/min will be identified. Measurements on baseline exercise catheterization, echocardiography, left atrial strain and clinical characteristics will be assessed for their ability to predict exercise capacity improvement by logistic regression.</description>
  </other_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with and without DNA will both be retained.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients will be identified from screening of the pulmonary hypertension clinic&#xD;
        who are then planned for outpatient catheterization for diagnosis and management of their&#xD;
        atypical PAH.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Pulmonary hypertension with mean PA pressure &gt;20 mmHg and a planned initiation of&#xD;
             pulmonary arterial hypertension therapy&#xD;
&#xD;
          -  No active treatment for precapillary pulmonary hypertension&#xD;
&#xD;
          -  Ambulatory (not wheelchair/scooter dependent)&#xD;
&#xD;
          -  Presence of any risk factor for left heart disease will qualify for inclusion (either&#xD;
             atrial fibrillation, body mass index&gt;30 kg/m2, arterial hypertension, diabetes,&#xD;
             coronary artery disease or age&gt;60 years)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant chronic obstructive pulmonary disease that is a primary contributor to&#xD;
             symptoms in the opinion of the investigator&#xD;
&#xD;
          -  Ischemia thought to contribute to dyspnea in the opinion of the investigator&#xD;
&#xD;
          -  Obstructive hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Known infiltrative cardiomyopathy (amyloid)&#xD;
&#xD;
          -  Constrictive pericarditis or tamponade&#xD;
&#xD;
          -  Active myocarditis&#xD;
&#xD;
          -  Complex congenital heart disease&#xD;
&#xD;
          -  More than mild aortic or mitral stenosis&#xD;
&#xD;
          -  Intrinsic (prolapse, rheumatic) valve disease with more than moderate mitral,&#xD;
             tricuspid or aortic regurgitation&#xD;
&#xD;
          -  Acute or chronic severe liver disease as evidenced by any of the following:&#xD;
             encephalopathy, variceal bleeding, INR &gt; 1.7 in the absence of anticoagulation&#xD;
             treatment&#xD;
&#xD;
          -  Terminal illness (other than HF) with expected survival of less than 1 year&#xD;
&#xD;
          -  Enrollment or planned enrollment in another therapeutic clinical trial in next 3&#xD;
             months.&#xD;
&#xD;
          -  Inability to comply with planned study procedures&#xD;
&#xD;
          -  Pregnancy or breastfeeding mothers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yogesh N Reddy, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yogesh Reddy, MBBS</last_name>
      <phone>507-284-3687</phone>
      <email>reddy.yogesh@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yogesh N. V. Reddy, M.B.B.S.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Right Heart Catheterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

